Liquidia Corporation reported net product sales of YUTREPIA totaling $51.7 million for the third quarter of 2025, marking its first full quarter of profitability since launch. Net loss for the period was $3.5 million, or $0.04 per basic and diluted share, compared to a net loss of $31.0 million, or $0.40 per share, in the same quarter of 2024. Research and development expenses decreased to $9.3 million from $11.9 million, primarily due to reduced personnel and facility costs, partially offset by higher clinical expenses for the L606 program. Total other expense, net, rose to $5.3 million from $1.8 million, mainly due to increased borrowings under the HCR Agreement. As of October 30, 2025, Liquidia received more than 2,000 unique patient prescriptions and 1,500 patient starts for YUTREPIA, supported by over 600 prescribers nationwide.